The pre-clinical data with SA-4-1BBL suggest that if a clinically suitable multimeric form of 4-1BBL can be developed; it may offer a compelling alternative to 4-1BB agonist antibody mediated stimulation for tumor immunotherapy. This evidence concerns the gene TNFRSF9 and neoplasm.